




AMENDMENT TRANSMITTAL LETTER (Small Entity)				Docket No. ALLIA.143A	
Applicant(s): Habib Zaghouani					
Serial No. 08/779,767	70572	Filing Date January 7, 1997	Examiner J. Reeves	Group Art Unit 1806 ✓	
Invention: Compounds, Compositions and Methods for the Endocytic Presentation of Immunosuppressive Factors					
<u>TO THE ASSISTANT COMMISSIONER FOR PATENTS:</u>					
Transmitted herewith is an amendment in the above-identified application.					
<input checked="" type="checkbox"/> Small Entity status of this application has been established under 37 CFR 1.27 by a verified statement previously submitted.					
<input type="checkbox"/> A verified statement to establish Small Entity status under 37 FR 1.27 is enclosed.					
The fee has been calculated and is transmitted as shown below.					
CLAIMS AS AMENDED					
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	65 -	65 =	0 x	\$11.00	\$0.00
INDEP. CLAIMS	8 -	8 =	0 x	\$40.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$0.00
<div style="float:right; border: 1px solid black; padding: 5px; transform: rotate(-10deg);">RECEIVED AUG 11 1997 GROUP 1800</div> <div><input checked="" type="checkbox"/> No additional fee is required for amendment.</div> <div><input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____ A duplicate copy of this sheet is enclosed.</div> <div><input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed.</div> <div><input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 01-1008 A duplicate copy of this sheet is enclosed.</div> <div><input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16.</div> <div><input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17.</div> <div style="text-align:right; margin-top: 20px;">Dated: 2 September 1997</div> <div style="margin-top: 20px;"> _____ Signature</div>					
<div>I certify that this document and fee is being deposited on 2 September 1997 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.</div> <div style="text-align:right; margin-top: 10px;"> _____ Signature of Person Mailing Correspondence</div> <div style="text-align:right; margin-top: 10px;">Christopher A. Dayton _____ Typed or Printed Name of Person Mailing Correspondence</div>					
CC:					

ALLIA.143A



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT

#6
B. Denny
9/19/97

Applicants : Zaghouni, H.) Group Art Unit 1806
Appl. No. : 08/779,767)
Filed : January 7, 1997)
For : COMPOUNDS, COMPOSITIONS)
AND METHODS FOR THE)
ENDOCYTIC PRESENTATION OF)
IMMUNOSUPPRESSIVE FACTORS)
Examiner : J. Reeves)

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on

9/2/97

Christopher Dayton

Christopher Dayton, Reg. No. 35,114

RESPONSE TO REQUIREMENT FOR RESTRICTION

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED
AUG 1 / 1997
GROUP 1800

Dear Sir:

Claims 1-65 are currently pending in the above-identified patent application. The claims generally relate to compounds and compositions for regulation of the immune system, their use and their formation.

In a requirement for restriction dated 1 August 1997, it is alleged that the claims, as presently written, are directed to several inventions. As set forth in the subject Official Action, Group I (claims 1-11, 22-29) is drawn to an Fc receptor ligand and immunosuppressive factor fusion, classified in class 514, subclass 12. The claims of Group II (claims 12-21), are held to be directed to recombinant methods of making immunomodulating compounds classified in class 435, subclass 69.6. Group III (claims 30-38) is held to comprise claims directed to methods for